Clinical Trials Logo

Clinical Trial Summary

The objective of this study is to quantify salivary oxidative stress biomarkers in patients with temporomandibular disorders and to quantify recently isolated endogenous peptide opiorphin in saliva of these patients. As chronic exposure to stress may cause hyperalgesia as a result of the stress response in the hypothalamic-pituitary-adrenal axis, aim is to test this as an underlying mechanism by correlating opiorphin and oxidative stress markers to salivary cortisol levels. The aim is to assess the association of oxidative stress salivary biomarkers with muscle and joint pain and to measure opiorphin, a potential biomarker of different pathological states.


Clinical Trial Description

Temporomandibular disorders (TMD) are most common chronic orofacial pain conditions of non-dental origin, with prevalence in the general population of 3.6% to 7%. Despite signs and symptoms being well described in the literature, there is still an absence of underlying pathophysiological mechanisms. Evidence based strategies for diagnosis and management of temporomandibular pain still aren't available. Psychological and mechanical stress factors could contribute to oxidative stress (OS) and lead to TMD. Therefore, identification of oxidative stress biomarkers would objectively indicate implication of OS in TMD pain onset mechanisms, and provide a basis for early detection, and a potential target for therapeutic agents to prevent progression to more severe dysfunction.

Aim is to quantify salivary OS markers and total antioxidant capacity (TAC), as well as recently isolated endogenous peptide opiorphin (OP) (2006 Inst. Pasteur), in TMD patients and compare them to controls. As chronic exposure to stress may cause hyperalgesia as a result of the stress response in the hypothalamic-pituitary-adrenal (HPA) axis, aim is to test this as an underlying mechanism by correlating OP and OS markers to salivary cortisol (SC) levels.

Hypotheses: OS has a role in TMD onset and maintenance, thus salivary markers of OS will increase and/or TAC will decrease; OP influences orofacial pain syndromes, such as TMD, and its salivary level will differ between TMD patients and controls. If decreased OP levels in TMD patients were encountered, we hypothesize that OP downregulation contributes to TMD onset as its analgesic effect is absent. Conversely, increased OP levels would suggest that OP is upregulated merely as a reaction to painful stimuli. Disbalanced SC levels in TMD patients would corroborate involvement of HPA axis in TMD mechanism, which is known to affect the intensity of OS.

Saliva of 50 TMD patients (diagnosed by validated diagnostic criteria and MRI) and 50 controls will be collected. OS markers (8-hydroxydeoxyguanosine, malondialdehyde, etc.) will be assessed by ELISA with spectrophotometric detection and by spectrophotometric reagent kits. OP levels will be measured by HPLC-MS/MS method, originally developed and validated by team members. The electrochemiluminescence immunoassay ECLIA will be used for measuring SC.

Pain and stress will be subjectively assessed using questionnaires: all subjects will fill in Perceived Stress Scale 10 (PSS-10); in TMD patients the worst experienced pain will be recorded using Visual Analogue Scale at the initial and at subsequent visits, as well as Graded Chronic Pain Scale (GCPS), Visual Analogue Scale (VAS), Patient Health Questionnaire (PHQ), Jaw function limitation scale (JFLS), Oral Behaviours Checklist and Oral Health Impact Profile (OHIP)-14.

TMD patients will be randomized in 2 treatment groups (1: stabilization splint + placebo pills; 2: placebo splint + 1g of vitamin C daily). Measurements will be repeated after 3 and 6 months of treatment. Monitoring of OP, OS markers and SC during that period will, depending on observed changes in TMD symptoms, further elucidate underlying proposed mechanism by performing multivariate analyses including treatment outcomes.

This translational research aims to make basic science findings useful for clinical applications. Findings of higher concentrations of OS biomarkers would, besides their significance as "a piece of puzzle" of TMD mechanism, could also be important in establishment of TMD diagnosis and as prospective therapeutic targets. Salivary opiorphin, due to its proven analgesic effect might additionally serve as a possible drug for orofacial pain syndromes.

Novel approach to understanding neuroendocrine mechanisms in TMD and their links to OS, as well and use of saliva as non-invasively available diagnostic biofluid represent significant scientific advances. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03029494
Study type Interventional
Source Croatian Science Foundation
Contact Iva Z Alajbeg, PhD
Phone 00385917930164
Email ialajbeg@sfzg.hr
Status Recruiting
Phase N/A
Start date October 1, 2015
Completion date September 30, 2019

See also
  Status Clinical Trial Phase
Completed NCT02839967 - Influence of Intraoral Photobiomodulation in Individuals With Temporomandibular Joint Dysfunction N/A
Completed NCT01659840 - Efficacy of Red and Infrared Lasers in Treatment of Temporomandibular Disorders N/A
Recruiting NCT05720065 - Peripheral TMD Pain Mechanisms and the Effect by Botulinum Toxin A Phase 2
Completed NCT03339739 - Effects of Mandibular Exercises Effect on Pain Perception and Sensitivity in Mandibular Myofascial Pain N/A
Recruiting NCT05607823 - Adding Core Stabilization Training to Manuel Therapy in Temporomandibular Disorders N/A
Completed NCT04948320 - Temporomandibular Dysfunction Affects Neck Disability, Headache, Anxiety, And Sleep Quality In Women: A Cross-Sectional Study
Recruiting NCT04726683 - Dry Needling vs Injection in Patients With Temporomandibular Disorders N/A
Completed NCT01201512 - CONDOR Temporomandibular Muscle and Joint Disorders (TMJD) Survey N/A
Completed NCT04098952 - Effects of Electric Massage on the Cervical Region in Subjects Diagnosed With Temporomandibular Disorders N/A
Completed NCT03926767 - Additional Effect of Pain Neuroscience Education to Orofacial and Neck Exercises in Temporomandibular Disorders N/A
Recruiting NCT05902026 - The BETY-Biopsychosocial Questionnaire (BETY-BQ) in Individuals With Temporomandibular Dysfunction-Related Headache
Completed NCT03736408 - Frequency of Occurrence of the Pain Form of Temporomandibular Joint Dysfunction
Recruiting NCT04694274 - Genetic Polymorphisms and Their Association With Temporomandibular Disorders
Recruiting NCT01544439 - Occlusal Splint and Counseling to Temporomandibular Disorder Phase 3
Completed NCT01535378 - Interest of Behavioural Reeducation in Dysfunctions of Masticatory Apparatus. Relations Between Parafunctions and Dysfunctions of Mastixatory Apparatus N/A
Completed NCT02380105 - Effectiveness of a Counseling Program for Temporomandibular Disorders (TMD) Treatment N/A
Completed NCT02230371 - Study on the Effect of Granisetron on Myofascial Pain in the Orofacial Muscles Phase 4
Recruiting NCT03990662 - What Are the Clinical Factors Associated With a Significant Pain Reduction Following Physiotherapy in Patients With Temporomandibular Disorders?
Recruiting NCT05927545 - Efficacy of Manuel Therapy and BETY in Patients With Temporomandibular Dysfunction Related Headache N/A
Completed NCT04857294 - Unilateral TMJ Discectomy Without Interposal Material in Patients With Disc Perforation or Fragmentation N/A